Thermo Fisher Considers Buying $8 Billion Diagnostics Firm Qiagen

诊断设备制造商Thermo Fisher考虑以80亿美元收购Qiagen NV

2019-11-14 13:00:06 YAHOO!FINANCE

本文共1378个字,阅读需4分钟

-- Thermo Fisher Scientific Inc., the maker of diagnostic equipment, is considering a purchase of molecular testing firm Qiagen NV in what could become one of its biggest-ever acquisitions, people with knowledge of the matter said. Thermo Fisher has approached the Dutch company about a potential deal, said the people, who asked not to be identified because the information is private. Qiagen, which is listed in New York and Frankfurt, has a market value of about $7.3 billion. There’s no certainty the deliberations will lead to a transaction, and other bidders for Qiagen could emerge, the people said. Qiagen’s American depositary receipts rose 9.9% to $35.45 in New York trading Wednesday, giving the company a market value of about $8 billion. Thermo Fisher’s shares were trading up 1.4% to $300.02, valuing it at more than $120 billion. The potential transaction could become one of Thermo Fisher’s largest purchases, surpassing its $5 billion takeover of drug-ingredient maker Patheon NV in 2017, according to data compiled by Bloomberg. Its largest acquisition was its $15 billion purchase of Life Technologies Corp. in 2014, the data shows. Deal Pipeline U.K. scientific measurement testing company LGC Group also has attracted sale interest. The private equity firm Cinven has teamed up with the Abu Dhabi Investment Authority to weigh a joint bid for the KKR & Co.-backed company, people familiar with the matter have said. Thermo Fisher Chief Executive Officer Marc Casper told analysts last month he feels “great” about the company’s mergers and acquisitions pipeline, which “continues to be very active.” Representatives for Thermo Fisher, based in Waltham, Massachusetts, couldn’t immediately comment. Representatives for Qiagen didn’t immediately respond to a request for comment after business hours in the Netherlands. Qiagen’s Leadership Qiagen CEO Peer Schatz announced last month that he will step down after 27 years at the company, saying it’s time to bring in new leadership. Senior Vice President Thierry Bernard will act as interim CEO until a permanent successor is found. The company also cut its quarterly estimate for sales growth, sending its shares plunging the most in 17 years. Top medical device makers have the capacity to take on additional debt to finance acquisitions, according to Bloomberg Intelligence. Last year, Thermo Fisher rival Medtronic Plc agreed to buy the shares it doesn’t already own in Mazor Robotics Ltd. in a deal valuing the company at about $1.6 billion. (Updates with closing share price in fourth paragraph) --With assistance from Aaron Kirchfeld. To contact the reporters on this story: Ed Hammond in New York at ehammond12@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Nabila Ahmed in New York at nahmed54@bloomberg.net To contact the editors responsible for this story: Ben Scent at bscent@bloomberg.net, ;Liana Baker at lbaker75@bloomberg.net, Michael Hytha, Matthew Monks For more articles like this, please visit us at bloomberg.com ©2019 Bloomberg L.P.
据知情人士透露,诊断设备制造商 Thermo Fisher Scientific Inc .正考虑收购分子检测公司 Qiagen NV ,这可能成为该公司有史以来最大的收购之一。 知情人士表示,赛默飞世尔已经就一项潜在交易与这家荷兰公司进行了接洽。这些人要求不透露姓名,因为这些信息是保密的。Qiagen 在纽约和法兰克福上市,市值约73亿美元。 知情人士表示,目前尚不能确定谈判是否会达成交易,而其他竞购方也可能出现。 周三, Qiagen 在纽约市场的美国存托凭证上涨9.9%,至35.45美元,市值约80亿美元。Thermo Fisher 股价上涨1.4%,至300.02美元,估值超过1200亿美元。 据彭博社采集数据显示,这笔潜在交易可能成为 Thermo Fisher 规模最大的收购交易之一,超过其2017年以50亿美元收购药物成分生产商 Patien NV 的交易。数据显示,该公司最大的一笔收购是2014年以150亿美元收购 Life Technologies Corp .。 交易管道 英国科学测量测试公司 LGC 集团也吸引了销售兴趣。知情人士表示,私募股权公司 Cinven 已与阿布扎比投资局( Abu Dhabi Investment Authority )合作,考虑联合竞购 KKR & Co 支持的公司。 Thermo Fisher 首席执行官 Marc Casper 上个月对分析师说,他对公司的并购渠道感到“很棒”,因为“仍然非常活跃”。 位于马萨诸塞州沃尔瑟姆的 Thermo Fisher 公司的代表不能立即发表评论。Qiagen 公司的代表在荷兰工作时间结束后没有立即回复记者的置评请求。 Qiagen 的领导 Qiagen 首席执行官 Peer Schatz 上个月宣布,他将在公司任职27年后辞职,并表示现在是引入新领导的时候了。高级副总裁 ThierryBernard 将担任临时 CEO ,直到找到永久继任者。该公司还下调了季度销售增长预期,导致其股价创下17年来的最大跌幅。 彭博资讯( Bloomberg Intelligence )表示,顶级医疗设备制造商有能力承担额外债务,为收购提供资金。去年,赛默飞世尔的竞争对手美敦力公司( Medtronic Plc )同意以16亿美元的价格收购其在马佐机器人有限公司( Mazor Robotics Ltd .)尚未拥有的股份。 (更新第四段之收市价) --在 Aaron Kirchfeld 的协助下。 与记者联系: Ed Hammond in New York at ehammd12@ bloomberg.net ; Dinesh Nair in London at dnair5@ bloomberg.net ; Nabila Ahmed in New York at nahmed54@ bloomberg.net 联系负责这篇报道的编辑: Ben Scent at bscent @ bloomberg.net ; Lina Baker at lbaker75@ bloomberg.net , Michael Hytha , Matthew Monks 更多这样的文章,请访问我们在布隆伯格。com ©2019 Bloomberg L.P .

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文